Donna de Levante Raphael

Dr. Donna de Levante Raphael

Alzheimer's Foundation of America, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2022 in Medicina
Verified
Journal Article
Open access
PDF file
DRDonna de Levante Raphael
Donna de Levante Raphael
Primary care physicians play a vital role in the clinical care of their patients, early identification of dementia, and disease advocacy. It is essential to assess the knowledge and attitudes of physicians in the diagnosis of Alzheimer’s disease and other dementias. In primary care, the diagnosis of Alzheimer’s disease is often missed or delayed. With the increased prevalence of Alzheimer’s disease and the growing impact of dementia on health care resources, early detection by primary care physicians (PCP) is essential. Thus, their knowledge and attitudes about early detection and diagnosis are crucial. To examine the knowledge and attitudes of primary care physicians regarding early detection and diagnosis of Alzheimer’s disease and how barriers may contribute to missed and delayed detection and diagnosis. An interpretive scope review was used to synthesize and analyze a body of literature published over the past decade. The study population are physicians in the United States. The current health systems experience challenges in providing early, safe, accurate, and comprehensive Alzheimer’s diagnosis and care by a primary care physician trained or knowledgeable in diagnosing the various forms of dementia. This article identifies several interrelated obstacles to early detection and diagnosis in primary dementia care, including gaps in knowledge, attitudes, skills, and resources for person with dementia (PWD)/caregivers and their primary care providers and systematic and structural barriers that negatively impact dementia care. Research shows that Alzheimer’s disease has gone underdiagnosed and undertreated. Delays in detection, diagnosis, and resource utilization may have social and clinical implications for individuals affected by Alzheimer’s disease and their families, including challenges in obtaining an accurate diagnosis. Until the issues of missed and delayed Alzheimer’s screening become more compelling, efforts to promote early detection and diagnosis should focus on the education of physicians and removing the barriers to diagnosis.

1 January 2022 in AIMS Public Health
Verified
Journal Article
Open access
PDF file
ARAllison B. Reiss
Allison B. Reiss
DRDonna de Levante Raphael
Donna de Levante Raphael
NCNathaniel A. Chin
Nathaniel A. Chin
VSVivek Sinha
Vivek Sinha
Primary care professionals play a critical role in the care of their patients. In clinical practice, early detection and diagnosis of Mild Cognitive Impairment, Alzheimer's disease and related dementia are often missed or delayed. Disclosure of diagnosis is not timely or not revealed. Though the methods that could improve early detection and diagnosis have remained the same over the decades with little change, they provide opportunities for early intervention, treatment and improvement in patient care. Emerging research suggests that though the disease process begins years prior to the clinical diagnosis, the healthcare system and health care professionals remain distant and reluctant to provide the service of annual cognitive assessment, which has been recommended by the Medicare program for older adults aged 65 years and older. Findings support that Alzheimer's disease and related cognitive impairments have gone under detected, underdiagnosed and undertreated. This article seeks to provide valuable and equitable information in the form of a clinician's guide for removing the barriers to early detection and diagnosis of cognitive impairments and offers an unprecedented opportunity to improve the clinical outcomes and care of older adults with various levels of cognitive decline, including mild cognitive impairment, Alzheimer's disease, and related dementias. This article provides information on understanding and addressing the challenges faced by health care professionals, including primary care clinicians; removing the barriers to cognitive assessments; educating this professional group on the importance of brain health, early detection, and diagnosis for their older adult patients; and providing these professionals with the ability to transfer their knowledge into more defined care planning. Until cognitive screening has been fully accepted and implemented for the optimal the care of older adults, health-related efforts should include the promotion and education of brain health, early detection, and diagnosis in the education of health care providers.

1 January 2025 in AIMS Neuroscience
Verified
Journal Article
Open access
PDF file
DRDonna de Levante Raphael
Donna de Levante Raphael
Background Alzheimer's disease (AD) and mild cognitive impairment (MCI) are widely recognized for their hallmark cognitive deficits, typically characterized by progressive cognitive deterioration. However, neuropsychiatric symptoms (NPS), including depression, apathy, anxiety, irritability, and sleep disturbances, are increasingly prevalent in the early stages of these conditions and significantly influence the disease trajectory and patient outcomes. Importantly, neuropsychiatric symptoms often precede overt memory loss by several years, with subtle mood and behavioral disturbances serving as early pre-diagnostic markers of an underlying Alzheimer's pathology. Their presence complicates the diagnosis, accelerates the disease progression, and intensifies the caregiver burden. However, distinguishing NPS arising from neurodegeneration and primary psychiatric disorders remains a profound diagnostic challenge, thus delaying timely intervention and obscuring early disease recognition. Objective This structured narrative review examines the diagnostic complexities, clinical impact, and current management of NPS in early-stage Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), alongside the biological underpinnings, clinical relevance, diagnostic challenges, and treatment perspectives. We argue that understanding and managing NPS is essential to improve the clinical outcomes, reduce the caregiver burden, and guide therapeutic innovation. Methods A structured narrative review of peer-reviewed studies published between 2012 and 2025 was conducted using PubMed, MEDLINE, Scopus, PsycINFO, Google Scholar, and CINAHL. The included studies investigated NPS prevalence, neurobiological correlations, and management strategies in individuals with AD or MCI. Findings NPS affects up to 80% of individuals with early AD or MCI, often preceding cognitive decline. The current management strategies heavily rely on non-pharmacological interventions such as caregiver support, behavioral activation, and structured routines, while pharmacological options remain limited by modest efficacy and safety concerns. Discussion Advancing knowledge of NPS and their association with cognitive decline is critical to establish more precise diagnostic criteria and to inform personalized therapeutic approaches. Future research should emphasize biomarker-driven diagnostics and the development of novel, targeted interventions that simultaneously address cognitive and neuropsychiatric domains to optimize outcomes for patients and caregivers. This study contributes to the field by reframing NPS as potential early biomarkers in the trajectory of MCI and dementia progression.

21 April 2026 in Medicina
Verified
Journal Article
Open access
PDF file
DRDonna de Levante Raphael
Donna de Levante Raphael
LKLora Janis Kasselman
Lora Janis Kasselman
WDWendy Anne Drewes
Wendy Anne Drewes
IWIsabella Wolff
Isabella Wolff
LBLuke Betlow
Luke Betlow
ARAllison B Reiss
Allison B Reiss
Dementia caregiving represents a major public health challenge, with spousal caregivers assuming the greatest burden. Spouses, themselves typically older adults, provide high intensity, long-term, and largely unpaid care across all stages of cognitive decline. Despite their central role in dementia care, the health consequences experienced by spousal caregivers remain insufficiently characterized in the literature and inadequately addressed in clinical and public health practice. This structured narrative review synthesizes current evidence on the multidimensional impact of dementia caregiving on the physical, psychological, cognitive, social, and financial health of spousal caregivers. It further contextualizes these consequences within the trajectory of dementia progression, and identifies interventions, support systems, and policy considerations necessary to mitigate caregiver burden. Spousal caregivers experience disproportionate burden due to continuous, escalating responsibilities that often mirror the progressive deterioration of their partners. Emotional burdens, including uncertainty during pre-diagnostic stages, role strain, conflict, loss of intimacy, and anticipatory grief. Physically, spouses endure musculoskeletal strain, sleep disruption, poor nutrition, and heightened frailty risk. Psychologically, spousal caregivers exhibit elevated rates of depression, anxiety, loneliness, and stress-related disorders. Socially, caregivers experience substantial isolation, stigma, and erosion of social networks. Financial hardship, including early retirement, reduced employment, and uncompensated care hours, further exacerbate stress. Evidence suggests that chronic caregiving stress contributes to biological changes such as immune dysregulation, inflammation, acceleration, aging, and potential cognitive decline in caregivers themselves. Caregiver burden influences patient outcomes as evidenced by increased emergency department use, falls, and earlier institutionalization in persons with dementia whose caregiver is subjected to a high burden. Current care models rarely include routine, caregiver assessment or structured guidance following diagnosis, resulting in substantial unmet needs. Effective mitigation requires integrated, stage-sensitive interventions, including psychosocial support, caregiver education, respite services, culturally tailored programs, and digital health tools, alongside broader policy reforms to reduce financial and structural barriers.

12 February 2026 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
DRDonna de Levante Raphael
Donna de Levante Raphael
Background: Alzheimer’s disease (AD) and mild cognitive impairment (MCI) are traditionally defined by progressive cognitive decline, yet neuropsychiatric symptoms (NPS), including depression, apathy, anxiety, irritability, and sleep disturbances, commonly emerge in the earliest stages. These symptoms often precede measurable memory loss and complicate diagnosis, accelerate disease progression, and substantially increase caregiver burden. Differentiating NPS related to neurodegeneration from primary psychiatric disorders remains a major clinical challenge. Methods: A structured narrative review of peer-reviewed studies (2012–2025) was conducted across PubMed, MEDLINE, Scopus, PsycINFO, CINAHL, and Google Scholar. Evidence was synthesized across epidemiological, clinical, neurobiological, and psychosocial domains to examine NPS prevalence, diagnostic complexity, and treatment approaches in early AD/MCI. Findings Up to 80% of individuals with early AD or MCI exhibit at least one NPS, often before cognitive decline is clinically evident. Non-pharmacologic strategies-caregiver education, behavioral activation, structured routines-remain first-line treatments, while pharmacologic options show modest benefit and safety concerns. Advances in biomarkers, digital health tools, and neurobiological research highlight NPS as potential early indicators of disease onset. Conclusions: Failure to recognize NPS in early AD/MCI contributes to delayed diagnosis, suboptimal care, caregiver stress, and missed opportunities for early intervention. Integrating systematic NPS assessment into diagnostic and care pathways is essential to improving outcomes and advancing therapeutic innovation.

6 April 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
DRDonna de Levante Raphael
Donna de Levante Raphael
Early identification of Alzheimer's disease remains restricted due to overreliance on cognitive testing and biomarker accessibility. The study by Ghahremani et al. demonstrates that persistent, however not transient, functional impairment in cognitively normal older adults robustly predicts incident cognitive decline and dementia. This commentary positions their findings within social, behavioral, and public-health frameworks, emphasizing functional trajectories as ecologically valid, scalable markers of preclinical disease. By operationalizing function through persistence over time, this work advances dementia projections beyond cross-sectional assessment and supports integration of functional monitoring into population-level prevention, clinical trials, and equity-focused early detection strategies.